biotechnology
Beyond Market Intelligence keeps biotechnology in one place: 9 stories so far. The section currently leads with “Voice loss sparked this founder's mission to restore emotion in speech”, “AI Biotech Enveda Accelerates Drug Development with $311M Investment”, and “Anthropic's biology lab tests the promise and peril of AI-driven science”. Losing your voice means losing a piece of who you are. Enveda's $311M raise isn't just a big number; it's a signal that AI-driven drug discovery is moving from promise to pipeline. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work… The list below is every biotechnology story on Beyond Market Intelligence, newest first.
Voice loss sparked this founder's mission to restore emotion in speech
Losing your voice means losing a piece of who you are. That's the spark behind Uhura Bionics, part of the Startup Battlefield 200 at TechCrunch Disrupt. The founder watched robotic, flat speech fail to carry real feeling, and set out to change that. This isn't just about clearer sound; it's about restoring the emotion that makes us human. It's a mission worth hearing. For more on founders turning personal pain into progress, explore how travel leads Instinct's daily growth with 10% momentum.
AI Biotech Enveda Accelerates Drug Development with $311M Investment
Enveda's $311M raise isn't just a big number; it's a signal that AI-driven drug discovery is moving from promise to pipeline. The $2B valuation reflects real momentum, especially as the company targets skin conditions and tackles the stubborn problem of weight regain after GLP-1s. That's practical science with tangible outcomes. We're watching a biotech that understands the patient's journey, not just the lab bench. For more on who's betting big on emerging tech, check our piece on Wahlberg and Lee's upcoming Disrupt discussion.
Anthropic's biology lab tests the promise and peril of AI-driven science
Anthropic is now running a lab that runs biology experiments, which puts the company at the center of two promises at once. AI leaders have long claimed this technology will cure human disease, while Anthropic's own researchers have warned it might end us. That tension is worth sitting with. It is not a contradiction; it is the actual shape of the work. If you are trying to make sense of how AI systems handle complexity, our piece on paragraph structure offers a useful parallel.
Explore how AI is reshaping the future of species revival
Not long ago, bringing an extinct species back to life was science fiction. Today, it's the mission of a billion-dollar startup, and it's happening now. At TechCrunch Disrupt 2026, we'll hear from one of tech's most unconventional founders on how AI can engineer nature's comeback. It's a bold, practical challenge to how we think about restoration. If you're curious about the mechanics behind such ambition, our related piece on verifying AI's understanding offers a grounded starting point. Secure your Disrupt pass today.
Living skin, alive for weeks, reveals new paths to discovery.
For years, living human skin tissue has been kept alive outside the body for just days. Michael Polansky's startup is stretching that to weeks, using the platform to test skincare compounds on something that more closely mirrors reality. It's a quiet, deliberate move from a former Sean Parker deputy, and it deserves attention. If you're exploring how AI is reshaping biotech, our guide to unlocking AI for work offers a practical starting point. This is discovery with a tangible human payoff.
Enhanced Games' $60 million loss shows steroids are no shortcut to success
The Enhanced Games promised a bold, steroid-fueled future for sports, but the market just delivered a $60 million reality check. That's a steep price for a vision that clearly isn't landing with the public or investors yet. We admire the audacity, but transformation requires more than defiance; it requires a solution people actually embrace. While we cover ambitious tech bets elsewhere, like Cloudflare's Blog finding performance gains with EmDash, this particular experiment shows that challenging convention without a viable path forward is a gamble.
Discover how better data unlocks AI's real potential in healthcare.
If AI is going to move the needle on cancer, it won't be through clever algorithms alone. This startup argues the real bottleneck is data, plain and simple. That's a refreshingly grounded take in a field prone to hype. We're not talking about magic; we're talking about feeding models the right, clean information. It's a messier problem than most want to admit, but it's the one that matters.
Colossal Biosciences eyes new funding to double its de-extinction valuation.
Colossal Biosciences is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion, a move that would double or triple its previous worth. That kind of ambition signals confidence in a mission that goes far beyond the lab. It's a bold bet on the future of genetic restoration, and one worth watching closely. For more on how AI-native infrastructure is reshaping similar ventures, check out our piece on Nscale's recent funding.
Explore how AI unlocks new discoveries in life sciences funding
Miles Wang, an OpenAI researcher, is reportedly in talks to launch an AI-driven drug discovery startup with a $2 billion valuation. That's a striking signal of where the industry sees the next breakthrough. Investors are betting that AI can tackle the messy, high-stakes work of life sciences, not just automate spreadsheets. It's a bold move, and one that feels overdue. For anyone tracking how AI moves beyond data management into real-world impact, this is worth watching closely.